抗体的亲和力与亲合力
抗体亲和力与亲合力的区别AffinityandAvidityofAntibodies.pdf
Affinity and Avidity of AntibodiesAntibody Affinityantigen Affinity measures the strength of interaction between an epitope and an antibody’s binding site. It is defined by the same basic thermodynamic principles that govern any reversible biomolecular interaction:o K A = affinity constanto[Ab] = molar concentration of unoccupied binding sites on the antibodyo[Ag] = molar concentration of unoccupied binding sites on the antigeno[Ab-Ag] = molar concentration of the antibody-antigen complexIn other words, K A describes how much antibody-antigen complex exists at the point when equilibrium is reached. The time taken for this to occur depends on rate of diffusion and is similarfor every antibody. However, high-affinity antibodies will bind a greater amount of antigen in a shorter period of time than low-affinity antibodies. K A can therefore vary widely for antibodies from below 105 mol-1 to above 1012 mol-1, and can be influenced by factors including pH, temperature and buffer composition.The affinity of monoclonal antibodies can be measured accurately because they are homogeneous and selective for a single epitope. Polyclonal antibodies are heterogeneous and will contain a mixture of antibodies of different affinities recognizing several epitopes –therefore only an average affinity can be determined.Antibody AvidityAvidity gives a measure of the overall strength of an antibody-antigen complex. It is dependenton three major parameters:o Affinity of the antibody for the epitope (see above)o Valency of both the antibody and antigeno Structural arrangement of the parts that interactAll antibodies are multivalent e.g. IgGs are bivalent and and IgMs are decavalent. The greater an immunoglobulin’s valency (number of antigen binding sites), the greater the amount of antigen it can bind. Similarly, antigens can demonstrate multivalency because they can bind to more thanone antibody. Multimeric interactions between an antibody and an antigen help their stabilization.A favorable structural arrangement of antibody and antigen can also lead to a more stable antibody-antigen complex as illustrated in Figures 1 and 2.Figure 1. An immobilized antigen (a high local concentration of available epitopes) provides more opportunity for the antibody-antigen complex to form than free antigen in solution over the same time period. Once the first antigen binding arm of an antibody attaches to an antigen on a solid support, the chances of a bivalent interaction are greatly improved. Many immunoassays like Western blotting and ELISA exploit this principle.Figure 2. When an antigen is mixed with a polyclonal antibody, multivalent interactions may leadto large, stable (high avidity) structures being formed. This is because the antigen may be boundby several antibodies, each recognizing a different epitope. Polyclonal antibodies are therefore ideal for immunoprecipitation experiments.Further Useful Readingo How we improve the affinity of our recombinant monoclonal antibodies generated using HuCAL? technology through affinity maturation。
抗原抗体结合的影响因素
转载某理工大学讲义，如果有更新的研究文章更好，呵呵第一节抗原抗体反应的原理抗原与抗体能够特异性结合是基于抗原决定簇(表位)与抗体超变区的沟槽分子表面的结构互性与亲合性而结合的。
一、抗原抗体的结合力抗原抗体间结合为非共价键结合，有四种分子间引力参与。
(1)静电引力：是抗原抗体分子带有相反电荷的氨基和羧基基团之间相互吸引的力。
又称为库伦引力。
这种引力的大小与两电荷间的距离的平方成反比。
两个电荷距离越近，静电引力越强。
(2)范登华引力：是抗原与抗体两个大分子外层轨道上电子之间相互作用时，因两者电子云中的偶极摆动而产生吸引力。
能促使抗原抗体相互结合，这种引力的能量小于静电引力。
(3)氢键结合力：是抗体上亲水基团与相应抗原彼此接近时，相互间可形成氢键，使抗原抗体相互结合。
氢键结合力较范登华引力强。
(4)疏水作用力：是抗原表位与抗体超变区靠近时，相互间正、负极性消失，亲水层也立即失去，排斥了两者之间的水分子，使抗原抗体进一步相互吸引，促进其结合。
疏水作用力是这些力中最强的，对维系抗原抗体结合作用最大。
二、抗原抗体的亲合性和亲合力亲合性是指抗体分子上一个抗原结合点与对应的抗原表位之间相互适应而存在的引力，它是抗原抗体之间固有的结合力，可用平衡常数K 来表示：K=K1/K2，K 值越大，亲合性越高；亲合性越高，与抗原结合越牢。
抗体的亲合力是指抗体结合部位与抗原表位之间结合的强度，与抗体结合价直接相关，即所谓多价优势，如IgG 为两价，亲合力为单价的103倍，IgM 为5～10 价，亲合力为单价的107倍。
由于抗原抗体的结合反应是可逆的，若抗体的亲合力高，与抗原分子结合牢固，不易解离；反之即容易解离。
三、亲水胶体转化为疏水胶体大多数抗原为蛋白质，抗体是球蛋白，它们溶解在水中皆为胶体溶液，不会发生自然沉淀。
这种亲水胶体的形成机制是因蛋白质含有大量的氨基和羧基残基，在溶液中这些残基带有电荷，由于静电作用，在蛋白质分子周围出现了带相反电荷的电子云并形成了水化层，由于电荷的相斥，就避免了蛋白质分子间靠拢、凝集和沉淀。
抗体亲和力与亲合力的区别Affinity and Avidity of Antibodies
Affinity and Avidity of AntibodiesAntibody AffinityAffinity measures the strength of interaction between an epitope and an antibody’s antigen binding site. It is defined by the same basic thermodynamic principles that govern any reversible biomolecular interaction:o K A= affinity constanto[Ab]= molar concentration of unoccupied binding sites on the antibodyo[Ag]= molar concentration of unoccupied binding sites on the antigeno[Ab-Ag]= molar concentration of the antibody-antigen complexIn other words, K A describes how much antibody-antigen complex exists at the point when equilibrium is reached. The time taken for this to occur depends on rate of diffusion and is similar for every antibody. However, high-affinity antibodies will bind a greater amount of antigen in a shorter period of time than low-affinity antibodies. K A can therefore vary widely for antibodies from below 105mol-1to above 1012mol-1, and can be influenced by factors including pH, temperature and buffer composition.The affinity of monoclonal antibodies can be measured accurately because they are homogeneous and selective for a single epitope. Polyclonal antibodies are heterogeneous and will contain a mixture of antibodies of different affinities recognizing several epitopes – therefore only an average affinity can be determined.Antibody AvidityAvidity gives a measure of the overall strength of an antibody-antigen complex. It is dependent on three major parameters:o Affinity of the antibody for the epitope (see above)o Valency of both the antibody and antigeno Structural arrangement of the parts that interactAll antibodies are multivalent e.g.IgGs are bivalent and and IgMs are decavalent. The greater an immunoglobulin’s valency (number of antigen binding sites), the greater the amount of antigen it can bind. Similarly, antigens can demonstrate multivalency because they can bind to more than one antibody. Multimeric interactions between an antibody and an antigen help their stabilization.A favorable structural arrangement of antibody and antigen can also lead to a more stable antibody-antigen complex as illustrated in Figures 1 and 2.Figure 1.An immobilized antigen (a high local concentration of available epitopes) provides more opportunity for the antibody-antigen complex to form than free antigen in solution over the same time period. Once the first antigen binding arm of an antibody attaches to an antigen on a solid support, the chances of a bivalent interaction are greatly improved. Many immunoassays like Western blotting and ELISA exploit this principle.Figure 2.When an antigen is mixed with a polyclonal antibody, multivalent interactions may lead to large, stable (high avidity) structures being formed. This is because the antigen may be bound by several antibodies, each recognizing a different epitope. Polyclonal antibodies are therefore ideal for immunoprecipitation experiments.Further Useful Readingo How we improve the affinity of our recombinant monoclonal antibodies generated using HuCAL® technology through affinity maturation。
亲和力的医学名词解释
亲和力的医学名词解释亲和力是医学领域的一个重要术语，也是许多医学研究的关键因素之一。
亲和力指的是物质与另一物质或组织之间的相互作用能力。
在医学中，亲和力的理解对于药物研发、抗体疗法以及组织移植等领域都具有重要意义。
亲和力最常见的应用之一就是药物研发领域。
当医药科学家开发新药物时，他们希望这些药物能够与目标细胞或病原体发生亲和作用。
亲和力的高低决定着药物能否在人体内正常生效。
例如，抗生素的亲和力决定了其是否能够对抗细菌感染。
如果抗生素与细菌的亲和力高，那么它将能够定位并杀死感染的细菌，从而治愈疾病。
除了药物研发，亲和力在抗体疗法中也扮演了重要角色。
抗体疗法致力于利用人体的自然免疫机制来对抗癌症和其他疾病。
抗体是由免疫系统产生的一类特殊蛋白质，具有与特定抗原发生亲和力的能力。
科学家们利用这种亲和力，将抗体与癌细胞相关的表面标记物连接起来，从而使免疫系统能够更有效地识别并攻击癌细胞。
亲和力的高低直接影响了抗体疗法的效果。
如果抗体与癌细胞的亲和力不足，那么抗体将无法准确地与癌细胞结合，无法起到治疗的作用。
亲和力还在组织移植领域发挥着重要作用。
组织移植是将一个人的组织或器官移植到另一个人的身体中，以治疗疾病或修复受损组织。
亲和力的概念在这一过程中非常重要。
如果移植物与受体的亲和力高，那么移植物将能够更好地融入受体的身体，并且减少排斥反应的风险。
因此，在进行组织或器官移植时，医生会仔细评估移植物与受体之间的亲和性，以确保手术的成功和受体的康复。
除了以上几个方面，亲和力还有许多其他应用，如在药物代谢研究、病毒学研究和分子生物学实验中起到重要作用。
通过对亲和力的研究和理解，科学家们能够更好地了解生物分子之间的相互作用，从而为医学科学的发展提供基础。
尽管亲和力在医学领域扮演着重要角色，但亲和力的研究也面临一些挑战和限制。
首先，亲和力的测定往往是一项复杂的任务，需要使用特殊的实验设备和技术。
其次，亲和力的研究结果受到许多因素的影响，如温度、PH值和离子浓度等。
亲合力
谢谢观看
尿素处理时间长短可影响AI的高低，尤其是低AI的标本会因为变性时间不足而得出明显高于真实的AI值。国 内的研究在检测抗HCMV-IgG AI时多采用简化的洗脱法，认为取50%为判断近期原发感染的界值。经比较2种方法 分别检测8份血浆的结果，温育法检测的AI低于洗脱法，但无显著性差异，说明温育法(变性孔尿素终浓度4mol/L) 与该洗脱法具有相近的使低亲合力抗体变性的能力。由此本研究采用Hedman对于AI的解释，以AI<30%判断近期原 发感染，以AI>30%排除近期原发感染，判断为既往感染或再发感染。
抗HCMV-IgG浓度过高时包被抗原相对不足，存在过剩的IgG，此时由于高亲合力的IgG在尿素的作用下仍然能 与包被抗原结合，而非变性孔IgG与包被抗原的结合已经饱和，所测得的A值相对恒定，因此影响AI测定，得出较 高的AI值。这与K li-mashevskaya等的报道一致。而Dangel等却认为高浓度的IgG会引起错误的低AI值结果，可 能与实验方法及试剂的不同有关。而在检测血浆抗HC-MV-IgG浓度约100 IU/mL的AI时，AI值随稀释倍数不同出 现一定的波动，但不影响结果的判断。
HSCs是肝纤维化形成过程中合成细胞外基质的最主要细胞，肝纤维化恢复期，凋亡的HSCs明显增多。实验证 明，在CCl4造成大鼠肝纤维化模型后的自动恢复过程中，HSCs凋亡是中心事件。所以，抑制HSCs增殖、诱导其凋 亡是抗肝纤维化的重要策略。Takahashi等报道，NGFR是细胞膜受体，存在于多种细胞表面。
抗体的亲和力与亲合力.pdf
Affinity and Avidity of AntibodiesAntibody Affinityantigen Affinity measures the strength of interaction between an epitope and an antibody’s binding site. It is defined by the same basic thermodynamic principles that govern any reversible biomolecular interaction:o K A = affinity constanto[Ab] = molar concentration of unoccupied binding sites on the antibodyo[Ag] = molar concentration of unoccupied binding sites on the antigeno[Ab-Ag] = molar concentration of the antibody-antigen complexIn other words, K A describes how much antibody-antigen complex exists at the point when equilibrium is reached. The time taken for this to occur depends on rate of diffusion and is similarfor every antibody. However, high-affinity antibodies will bind a greater amount of antigen in a shorter period of time than low-affinity antibodies. K A can therefore vary widely for antibodies from below 105 mol-1 to above 1012 mol-1, and can be influenced by factors including pH, temperature and buffer composition.The affinity of monoclonal antibodies can be measured accurately because they are homogeneous and selective for a single epitope. Polyclonal antibodies are heterogeneous and will contain a mixture of antibodies of different affinities recognizing several epitopes –therefore only an average affinity can be determined.Antibody AvidityAvidity gives a measure of the overall strength of an antibody-antigen complex. It is dependenton three major parameters:o Affinity of the antibody for the epitope (see above)o Valency of both the antibody and antigeno Structural arrangement of the parts that interactAll antibodies are multivalent e.g. IgGs are bivalent and andIgMs are decavalent. The greater an immunoglobulin’s valency (number of antigen binding sites), the greater the amount of antigen it can bind. Similarly, antigens can demonstrate multivalency because they can bind to more thanone antibody. Multimeric interactions between an antibody and an antigen help their stabilization.A favorable structural arrangement of antibody and antigen can also lead to a more stable antibody-antigen complex as illustrated in Figures 1 and 2.Figure 1. An immobilized antigen (a high local concentration of available epitopes) provides more opportunity for the antibody-antigen complex to form than free antigen in solution over the same time period. Once the first antigen binding arm of an antibody attaches to an antigen on a solid support, the chances of a bivalent interaction are greatly improved. Many immunoassays like Western blotting and ELISA exploit this principle.Figure 2. When an antigen is mixed with a polyclonal antibody, multivalent interactions may leadto large, stable (high avidity) structures being formed. This is because the antigen may be boundby several antibodies, each recognizing a different epitope. Polyclonal antibodies are therefore ideal for immunoprecipitation experiments.Further Useful ReadingHow we improve the affinity of our recombinant monoclonal antibodies generated usingHuCAL technology through affinity maturation。
临床免疫学检验名词解释重要知识点上
抗原抗体反应：是指抗原与相应抗体在体内或体外发生的特异性结合反应。
抗原抗体间的结合力涉及静电引力、范德华力、氢键和疏水作用力，其中疏水作用力最强，它是在水溶液中两个疏水基团相互接触，由于对水分子的排斥而趋向聚集的力。
亲和性（affinity）：是指抗体分子上一个抗原结合点与一个相应抗原表位（AD）之间的结合强度，取决于两者空间结构的互补程度。
亲合力（avidity）：是指一个完整抗体分子的抗原结合部位与若干相应抗原表位之间的结合强度，它与亲和性、抗体的结合价、抗原的有效AD数目有关。
抗原抗体反应的特点：特异性、可逆性、比例性、阶段性。
带现象（zone phenomenon）：一种抗原-抗体反应的现象。
在凝集反应或沉淀反应中，由于抗体过剩或抗原过剩，抗原与抗体结合但不能形成大的复合物，从而不出现肉眼可见的反应现象。
抗体过量称为前带，抗原过量称为后带。
免疫原（immunogen）：是指能诱导机体免疫系统产生特异性抗体或致敏淋巴细胞的抗原。
免疫佐剂（immuno adjustvant）：简称佐剂，是指某些预先或与抗原同时注入体内，可增强机体对该抗原的免疫应答或改变免疫应答类型的物质。
半抗原（hapten）：又称不完全抗原，是指仅具有与抗体结合的能力(抗原性)，而单独不能诱导抗体产生（无免疫原性）的物质。
当半抗原与蛋白质载体结合后即可成为完全抗原。
载体（carrier）：结合后能给予半抗原以免疫原性的物质。
载体效应：初次免疫与再次免疫时，只有使半抗原结合在同一载体上，才能使机体产生对半抗原的免疫应答，该现象称为~。
单克隆抗体（McAB）：将单个B细胞分离出来，加以增殖形成一个克隆群落，该B细胞克隆产生的针对单一表位、结构相同、功能均一的抗体，即~。
多克隆抗体（PcAb）：天然抗原分子中常含多种不同抗原特异性的抗原表位，以该抗原物质刺激机体免疫系统，体内多个B细胞克隆被激活，产生含有针对不同抗原表位的免疫球蛋白，即~基因工程抗体（GEAb）：是利用DNA重组及蛋白工程技术，从基因水平对编码抗体的基因进行改造和装配，经导入适当的受体细胞后重新表达的抗体。
简述抗体的基本结构
简述抗体的基本结构抗体是一种由蛋白质组成的分子，也称为免疫球蛋白。
它在免疫系统中起着至关重要的作用，能够识别并结合到体内外的抗原上，从而参与免疫应答的调节和效应。
抗体的基本结构可以分为四个区域：两个相同的轻链（light chain）和两个相同的重链（heavy chain）。
轻链和重链通过二硫键连接在一起，形成了Y形结构。
每个抗体分子都有两个臂和一个柄。
臂部位于抗体的顶端，具有抗原识别和结合的功能；柄部位于抗体的底部，具有效应分子结合的功能。
轻链是由单个多肽链组成的，重链则由两个多肽链组成。
轻链和重链都由一系列的可变区（variable region）和恒定区（constant region）组成。
可变区的序列在不同的抗体中具有高度的变异性，决定了抗体的特异性和亲和力。
恒定区的序列相对保守，决定了抗体的功能和效应。
抗体的可变区包括特异性决定区（hypervariable region），也称为CDR。
CDR位于可变区的末端，由三个短序列组成，分别命名为CDR1、CDR2和CDR3。
CDR通过氢键、疏水作用和范德华力等相互作用与抗原结合，形成抗原-抗体复合物。
抗体的恒定区在不同的抗体类别中有所不同，包括IgG、IgM、IgA、IgD和IgE等。
每种抗体类别具有不同的功能和在免疫反应中的作用。
例如，IgG是最常见的抗体类别，具有长时间的循环寿命和多种效应分子结合的能力；IgM是第一次免疫应答产生的主要抗体类别，具有较高的亲和力和多价结合能力。
在人体内，抗体由B淋巴细胞（B lymphocyte）产生。
当机体遇到外来的抗原时，B淋巴细胞会受到激活，开始分泌抗体。
这个过程称为免疫应答。
一旦抗体与抗原结合，它们可以通过多种机制来识别和清除抗原，包括中和病原体、激活补体系统、调节免疫细胞的活化等。
抗体的结构和功能使其成为疾病诊断和治疗的重要工具。
通过检测体液中的抗体水平，可以确定感染病原体的存在，并评估免疫系统对其的应答情况。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Affinity and Avidity of Antibodies
Antibody Affinity
Affinity measures the strength of interaction between an epitope and an antibody’s antigen binding site. It is defined by the same basic thermodynamic principles that govern any reversible biomolecular interaction:
o K A= affinity constant
o[Ab]= molar concentration of unoccupied binding sites on the antibody
o[Ag]= molar concentration of unoccupied binding sites on the antigen
o[Ab-Ag]= molar concentration of the antibody-antigen complex
In other words, K A describes how much antibody-antigen complex exists at the point when equilibrium is reached. The time taken for this to occur depends on rate of diffusion and is similar for every antibody. However, high-affinity antibodies will bind a greater amount of antigen in a shorter period of time than low-affinity antibodies. K A can therefore vary widely for antibodies from below 105mol-1to above 1012mol-1, and can be influenced by factors including pH, temperature and buffer composition.
The affinity of monoclonal antibodies can be measured accurately because they are homogeneous and selective for a single epitope. Polyclonal antibodies are heterogeneous and will contain a mixture of antibodies of different affinities recognizing several epitopes – therefore only an average affinity can be determined.
Antibody Avidity
Avidity gives a measure of the overall strength of an antibody-antigen complex. It is dependent on three major parameters:
o Affinity of the antibody for the epitope (see above)
o Valency of both the antibody and antigen
o Structural arrangement of the parts that interact
All antibodies are multivalent e.g.IgGs are bivalent and and IgMs are decavalent. The greater an immunoglobulin’s valency (number of antigen binding sites), the greater the amount of antigen it can bind. Similarly, antigens can demonstrate multivalency because they can bind to more than one antibody. Multimeric interactions between an antibody and an antigen help their stabilization.
A favorable structural arrangement of antibody and antigen can also lead to a more stable antibody-antigen complex as illustrated in Figures 1 and 2.
Figure 1.An immobilized antigen (a high local concentration of available epitopes) provides more opportunity for the antibody-antigen complex to form than free antigen in solution over the same time period. Once the first antigen binding arm of an antibody attaches to an antigen on a solid support, the chances of a bivalent interaction are greatly improved. Many immunoassays like Western blotting and ELISA exploit this principle.
Figure 2.When an antigen is mixed with a polyclonal antibody, multivalent interactions may lead to large, stable (high avidity) structures being formed. This is because the antigen may be bound by several antibodies, each recognizing a different epitope. Polyclonal antibodies are therefore ideal for immunoprecipitation experiments.
Further Useful Reading
How we improve the affinity of our recombinant monoclonal antibodies generated using HuCAL technology through affinity maturation。